Sienna Biopharmaceuticals' acne drug fails two trials

Sienna Biopharmaceuticals

30/07/2018 12:21

July 30 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O 
said on Monday two pivotal trials testing its acne treatment did
not meet their main goals of reducing inflammatory lesions on
patients' skin.
    Sienna, which went public about a year ago, said the trials
were testing its experimental treatment, SNA-001, along with
laser therapies on patients with moderate to severe acne
vulgaris.  urn:newsml:reuters.com:*:nGNXbgwLbQ
    Shares of the company fell 14 percent to $13.50 in premarket
trading.

 (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh
Kuber)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))